Here, we report a case of brigatinib-induced TLS after treatment with sequential anaplastic lymphoma kinase (<i>ALK</i>) inhibitors in a patient with advanced <i>ALK</i>-rearranged lung adenocarcinoma. This evidence concerns the gene ALK and lung adenocarcinoma.